MedTrace Logo

Interstitial Lung Disease is a Risk Factor for Cardiovascular Disease

NCT06539962 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 134

Last updated 2025-08-28

No results posted yet for this study

Summary

A group of Interstitial pulmonary fibrosis will be recruited from Assiut university hospital outpatient clinic.

Evaluation will be done regarding cardiovascular comorbidities (Cardiovascular comorbidities will be evaluated with thorough assessment including; history, ECG, Lipid profile and echocardiography).

Lipid profile, CRP and KL-6 level will be assessed for recruited personnel. Regression analysis will be used to identify risk factors for cardiovascular comorbidities among IPF patients.

Conditions

Interventions

DIAGNOSTIC_TEST

Krebs von den Lungen-6 (KL-6)

Krebs von den Lungen-6 (KL-6) will be evaluated for ability to predict cardiovascular comorbidities among IPF patients

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Waleed MD Gamal Elddin Khaleel, Ass. Prof. · Assiut University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2024-09-01
Completion
2024-10-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06539962 on ClinicalTrials.gov